Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer

The study is being conducted to evaluate the safety, tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy in subjects with locally advanced or metastatic pancreatic cancer.

Trial Details

NCT ID

NCT06547736

Phase

PHASE2

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

SHR-A2102 or/and HRS-4642
SHR-A1904 or/and HRS-4642
SHR-A1811 or/and HRS-4642
SHR-A2102, HRS4642 and Adebrelimab

Locations (sample)

Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

Patients volunteered to participate in this study and signed informed consent;
Age: ≥18 and ≤75 years old, male or female;
Advanced (metastatic or unresectable) pancreatic cancer; and subjects must have at least one measurable lesion as defined by RECIST v1.1;
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →